Skip to main content

Camp4 Therapeutics Corp 10-Q for FY2026 Q3

Camp4 Therapeutics Corp (CAMP)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 06, 2026

About this 10-Q

Camp4 Therapeutics Corp filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

The ASCEND Phase 1/2 clinical trial is expected to dose its first patient in the fourth quarter of 2026. Cash and cash equivalents were $124.5 million on September 30, 2026, expected to fund operations through the end of 2028. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$1.9M
up 138.9% from $795K a year earlier
Net loss
$28.96M
compared with a net loss of $15.1M a year earlier
Diluted EPS
-$0.37
compared with -$0.55 a year earlier